Table of Content

1. Key Insights

2. Executive Summary of Retinitis Pigmentosa (RP)

3. Retinitis Pigmentosa: Disease Background and Overview
3.1. Introduction
3.2. History
3.3. Facts about Retina
3.4. Signs and Symptoms
3.5. Causes of Retinitis Pigmentosa
3.6. Clinical Features
3.7. Classification of Retinitis Pigmentosa
3.7.1. Classification as per Japanese guidelines
3.8. Pathophysiology
3.9. Etiology
3.10. Genetics of Retinitis Pigmentosa
3.10.1. Types of non-syndromic RP inheritance
3.11. Diagnosis
3.11.1. Recommended Diagnostic Tests
3.11.2. Differential diagnosis of RP

4. Case Reports
4.1. A Case of Unilateral Retinitis Pigmentosa Associated with Full Thickness Macular Hole
4.2. Eleven-Year Follow-Up of a Japanese Retinitis Pigmentosa Patient with an HK1 Gene Mutation
4.3. Unilateral Retinitis Pigmentosa: Visual field changes in a 31-year-old female

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology Methodology
5.3. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM
5.4. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
5.5. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
5.6. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic Retinitis Pigmentosa in the 7MM
5.7. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa in the 7MM

6. United States Epidemiology
6.1. Assumptions and Rationale
6.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United States
6.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
6.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
6.5. Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic RP in the United States
6.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United States

7. EU5 Epidemiology
7.1. Germany Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany
7.1.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
7.1.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
7.1.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany
7.1.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany
7.2. France Epidemiology
7.2.1. Assumptions and rationale
7.2.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France
7.2.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
7.2.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
7.2.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France
7.2.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France
7.3. Italy Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy
7.3.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
7.3.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
7.3.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy
7.3.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy
7.4. Spain Epidemiology
7.4.1. Assumptions and Rationale
7.4.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain
7.4.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
7.4.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
7.4.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain
7.4.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain
7.5. United Kingdom Epidemiology
7.5.1. Assumptions and Rationale
7.5.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom
7.5.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
7.5.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
7.5.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the United Kingdom
7.5.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United Kingdom

8. Japan Epidemiology
8.1. Assumptions and Rationale
8.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan
8.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
8.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
8.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan
8.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan

9. SWOT Analysis

10. Appendix
10.1. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight



List of Figures


Figure 1 Structure of Retina
Figure 2 Normal Eye Anatomy Versus Eye Anatomy in Retinitis Pigmentosa
Figure 3 Typical Symptoms associated with RP
Figure 4 Typical Symptoms associated with RP
Figure 5 Classification of RP
Figure 6 Specific clinical diagnosis of RP
Figure 7 Pathophysiology of RP
Figure 8 Altered Retinoid Cycle Metabolic Pathway
Figure 9 Types of non-syndromic based on the inheritance pattern
Figure 10 Pattern of autosomal dominant RP inheritance
Figure 11 Pattern of autosomal recessive RP inheritance.
Figure 12 Pattern of X-linked RP inheritance
Figure 13 Altered Retinoid Cycle Metabolic Pathway
Figure 14 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017–2030)
Figure 15 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Figure 16 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Figure 17 Sub-Type Specific Diagnosed Prevalence of syndromic & Systemic RP in the 7MM (2017–2030)
Figure 18 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the 7MM (2017–2030)
Figure 19 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017–2030)
Figure 20 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017–2030)
Figure 21 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017–2030)
Figure 22 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017–2030)
Figure 23 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the US (2017–2030)
Figure 24 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017–2030)
Figure 25 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Figure 26 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Figure 27 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017–2030)
Figure 28 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany (2017–2030)
Figure 29 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017–2030)
Figure 30 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Figure 31 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Figure 32 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017–2030)
Figure 33 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France (2017–2030)
Figure 34 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017–2030)
Figure 35 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Figure 36 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Figure 37 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017–2030)
Figure 38 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy (2017–2030)
Figure 39 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017–2030)
Figure 40 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Figure 41 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Figure 42 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017–2030)
Figure 43 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain (2017–2030)
Figure 44 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the UK (2017–2030)
Figure 45 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Figure 46 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Figure 47 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017–2030)
Figure 48 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the UK (2017–2030)
Figure 49 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017–2030)
Figure 50 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017–2030)
Figure 51 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa RP in Japan (2017–2030)
Figure 52 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017–2030)
Figure 53 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan (2017–2030)
Figure 80 SWOT Analysis

 

List of Tables


Table 1 Summary of Retinitis Pigmentosa (RP) Epidemiology, and Key Events (2017–2030)
Table 2 Summary of Genes Implicated in RP
Table 3 Syndromic retinitis pigmentosa
Table 4 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017–2030)
Table 5 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Table 6 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Table 7 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the 7MM (2017–2030)
Table 8 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the 7MM (2017–2030)
Table 9 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017–2030)
Table 10 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017–2030)
Table 11 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017–2030)
Table 12 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017–2030)
Table 13 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the US (2017–2030)
Table 14 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017–2030)
Table 15 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Table 16 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Table 17 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017–2030)
Table 18 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany (2017–2030)
Table 19 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017–2030)
Table 20 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Table 21 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Table 22 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017–2030)
Table 23 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France (2017–2030)
Table 24 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017–2030)
Table 25 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Table 26 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Table 27 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017–2030)
Table 28 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy (2017–2030)
Table 29 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017–2030)
Table 30 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Table 31 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Table 32 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017–2030)
Table 33 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain (2017–2030)
Table 34 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the UK (2017–2030)
Table 35 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Table 36 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Table 37 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017–2030)
Table 38 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the UK (2017–2030)
Table 39 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017–2030)
Table 40 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017–2030)
Table 41 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017–2030)
Table 42 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017–2030)
Table 43 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan (2017–2030)